pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 90

Sales Botox Antibody Drugs 90

pharmaphorum

NOVEMBER 18, 2020

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 87

Sales Botox Antibody Drugs 87

pharmaphorum

NOVEMBER 4, 2020

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. The company has exclusive rights to the sell Aimovig outside the US, where Amgen records sales, with the exception of Japan.

Botox 90

Botox Sales Doctor Doctors 90

XTalks

NOVEMBER 1, 2024

In this blog, we highlight the top 20 best-selling neurology drugs to watch in 2024, based on 2023 sales statistics. We discuss each drug’s approved uses, sales performance and why they’ve become essential in the neurology space. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1.

FDA Approval 85

FDA Approval Drugs Botox Sales 85

The Pharma Data

AUGUST 1, 2021

AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1 billion of combined sales in the quarter,” said Richard A. Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0

Botox 52

Botox Cosmetics Trials Clinical Trials 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.

Sales 96

Sales Manufacturing FDA Approval Life Science 96